论文部分内容阅读
目的研究胃癌患者血清肿瘤型M2-丙酮酸激酶(tM2-PK)的含量与临床病理学参数的关系。方法运用ELISA法定量检测tM2-PK在胃癌、胃溃疡、及正常人血清中的含量。结果胃癌患者血清tM2-PK增高,明显大于胃溃疡(P<0·05)与正常人组(P<0·01)。肿瘤≥5cm者明显高于<5cm者(P<0·05);TNMⅢ,Ⅳ期者明显高于Ⅰ,Ⅱ期者(P<0·01);而淋巴结转移情况、肿瘤胃壁浸润深度及组织学分级对tM2-PK水平的影响无明显差异。以大于15U/ml为阳性者,胃癌组阳性率为64%,胃溃疡组假阳性率为20%,正常对照组假阳性率为6%。结论胃癌肿瘤代谢的改变可产生大量tM2-PK。血清肿瘤型M2-PK水平升高可为肿瘤大小和病期提供依据。
Objective To study the relationship between serum tumor M2-pyruvate kinase (tM2-PK) and clinicopathological parameters in patients with gastric cancer. Methods Quantitative detection of tM2-PK in gastric cancer, gastric ulcer and normal human serum by ELISA. Results The level of serum tM2-PK in gastric cancer patients was significantly higher than that in gastric ulcer patients (P <0.05) and normal subjects (P <0.01). The tumor size was significantly higher than 5 cm (P <0.05), and the TNM III and IV stages were significantly higher than those in stage Ⅰ and Ⅱ (P <0.01). However, the lymph node metastasis, There was no significant difference in the level of tM2-PK between different grades. The positive rate of gastric cancer was 64%, the positive rate of gastric ulcer was 20%, and the false positive rate of normal control was 6%. Conclusion Metabolic changes in gastric cancer produce large amounts of tM2-PK. Serum tumor type M2-PK levels may provide a basis for tumor size and disease.